Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NLS Pharmaceutics ( (NLSP) ) has shared an update.
On August 29, 2025, NLS Pharmaceutics announced the extension of its merger agreement with Kadimastem Ltd. to October 31, 2025. This extension allows more time to address comments from the U.S. Securities and Exchange Commission on the pending registration statement, demonstrating the parties’ commitment to completing the merger with diligence and adherence to regulatory requirements.
More about NLS Pharmaceutics
NLS Pharmaceutics is a Swiss-based company involved in the pharmaceutical industry, focusing on developing innovative therapies for central nervous system disorders. The company is engaged in a merger with Kadimastem Ltd., an Israeli company, to enhance its market position and expand its operational capabilities.
Average Trading Volume: 247,941
Technical Sentiment Signal: Sell
Current Market Cap: $7.91M
Learn more about NLSP stock on TipRanks’ Stock Analysis page.